Sv
Da
En
Fr
De
Deal History
Om oss
Om oss
Team
Våra kontor
Globalscope
Newsletter
Services
Corporate Finance
Skuldrådgivning
Equity Research
Tillväxtkapital
IPO Advisory
Industries
Företagstjänster
Internet och konsumentprodukter
Industri och verkstad
Sjuk- och hälsovård
Mjukvara och TMT
Research
Analysmaterial
Makro och marknad
Career
Events
Insights
News
Bolagsnyheter
Deal News
I pressen
Newsletter
Kontakt
Newsletter
Sv
Da
En
Fr
De
Main menu button
Worldwide
Worldwide
Canada
Denmark
France
Germany
Poland
Sweden
United Kingdom
USA
Team
Deals
Kontakt
Worldwide
Worldwide
Canada
Denmark
France
Germany
Poland
Sweden
United Kingdom
USA
Aktieanalys
Team
Deals
Kontakt
Nyheter
Alla
Abera Bioscience
Adventure Box
Adverty
All for One Group
ALM Equity
Alzecure Pharma
Alzinova
Angler Gaming
Arctic Minerals
BellPal Holding
Bentley Endovascular Group
Biosergen
Biovica
Boozt
Candles Scandinavia
Cantargia
Carlsquare
CellaVision
CombiGene
CSAM Health Group
DanCann Pharma
Ecoclime
edyoutec
Elicera Therapeutics
Enrad
Fable Media
Frequentis
FRISQ
Future Gaming
GHP Specialty Care
GIAB
Gubra
H&D Wireless
Hansa Biopharma
Hanza
Herantis Pharma
InCoax
Kancera
Medclair Invest
Medivir
Midsummer
Mindark PE
Modus Therapeutics
Moninvent
NeoDynamics
Nexam Chemical
Nischer Properties
Nodebis
Nosa Plugs
Observit
Orion Corporation
Pharmiva
Prolight Diagnostics
Raytelligence
Risk Intelligence
SBB i Norden
Sensec
Spotlight Group
Svenska Aerogel
Teneo AI
Thinc Jetty
Viva Wine Group
Ytrade Group
Zazz Energy
Zinzino
Alla
Analysmaterial
Bolagsnyheter
Deal News
Events
I pressen
Insights
Makro och marknad
23 sep 2024
Carlsquare Equity Research interview with Biosergen
Analysmaterial
Biosergen
12 sep 2024
Research update Biosergen: First patient treated in phase Ib study a success
Analysmaterial
Biosergen
05 jul 2024
Research update Biosergen: Taking the next clinical step
Analysmaterial
Biosergen
11 jun 2024
Equity Research Biosergen: Study permission received, BSG005 ready for testing in patients
Analysmaterial
Biosergen
13 mar 2024
Research update Biosergen: Rights issue to fund crucial step for lead project
Analysmaterial
Biosergen
07 mar 2024
Carlsquare Equity Research intervju med Biosergen (Engelska)
Analysmaterial
Biosergen
02 feb 2024
Equity research Biosergen: Rights issue to fund the next clinical step
Analysmaterial
Biosergen
16 jan 2024
Analys Biosergen: Licensiering till Alkem och inskickad CTA
Analysmaterial
Biosergen
08 dec 2023
Biosergen at Carlsquare Nordic life science investor day
Analysmaterial
Biosergen
16 aug 2023
Analys Biosergen, kv2 2023: lägre kostnader med förseningar i pipeline
Analysmaterial
Biosergen
29 mar 2023
Equity research Biosergen: Plans for speedy development of lead candidate
Analysmaterial
Biosergen
20 mar 2023
Initiation of coverage, Biosergen: Make antifungals great again
Analysmaterial
Biosergen